Pascal Biosciences and SōRSE Technology Announce Partnership for Cannabinoid Drug Development and Cancer Clinical Trials

Author's Avatar
Sep 14, 2020
Article's Main Image

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 14, 2020 / Pascal Biosciences Inc. (TSXV:PAS, Financial) ("Pascal") and SōRSE Technology Corporation ("SōRSE") have entered into a Collaborative Research Agreement (the "Agreement") to advance Pascal's PAS-393 into clinical testing. Pascal and SōRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors.